Recent newsflow includes solid interim results, which demonstrated value in Abzena’s integrated service proposition and hybrid business model, positive updates on a couple of Abzena inside products and a licensing agreement to commercialise a legacy asset to Trieza Therapeutics. We maintain our valuation at £112m, but expect upside as it progresses.
06 Jan 2017
Newsflow continues validating the rationale
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Newsflow continues validating the rationale
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
06 Jan 2017 -
Author:
Dr Linda Pomeroy -
Pages:
3
Recent newsflow includes solid interim results, which demonstrated value in Abzena’s integrated service proposition and hybrid business model, positive updates on a couple of Abzena inside products and a licensing agreement to commercialise a legacy asset to Trieza Therapeutics. We maintain our valuation at £112m, but expect upside as it progresses.